BRPI0511367B8 - uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo - Google Patents

uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo

Info

Publication number
BRPI0511367B8
BRPI0511367B8 BRPI0511367A BRPI0511367A BRPI0511367B8 BR PI0511367 B8 BRPI0511367 B8 BR PI0511367B8 BR PI0511367 A BRPI0511367 A BR PI0511367A BR PI0511367 A BRPI0511367 A BR PI0511367A BR PI0511367 B8 BRPI0511367 B8 BR PI0511367B8
Authority
BR
Brazil
Prior art keywords
composition
vip
active fragment
prophylactic
conditions
Prior art date
Application number
BRPI0511367A
Other languages
English (en)
Inventor
Annette Duggan Karen
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004903188A external-priority patent/AU2004903188A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Publication of BRPI0511367A publication Critical patent/BRPI0511367A/pt
Publication of BRPI0511367B1 publication Critical patent/BRPI0511367B1/pt
Publication of BRPI0511367B8 publication Critical patent/BRPI0511367B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)

Abstract

uso de uma composição, composição, uso de vip e/ou de um fragmento ativo do mesmo". a presente invenção está relacionada com composição e métodos para tratamento de determinadas condições cardiovasculares. em particular, ela está relacionada com o tratamento profilático ou terapêutico da fibrose miocardial ou condições associadas através da administração de composições compreendendo peptídeo intestinal vasoativo (vip) e/ou fragmento(s) ativo(s) do mesmo.
BRPI0511367A 2004-06-11 2005-06-10 uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo BRPI0511367B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004903188 2004-06-11
AU2004903188A AU2004903188A0 (en) 2004-06-11 Treatment of myocardial fibrosis
PCT/AU2005/000835 WO2005120545A1 (en) 2004-06-11 2005-06-10 Compositions and methods for treatment of cardiovascular disease

Publications (3)

Publication Number Publication Date
BRPI0511367A BRPI0511367A (pt) 2007-12-04
BRPI0511367B1 BRPI0511367B1 (pt) 2018-05-22
BRPI0511367B8 true BRPI0511367B8 (pt) 2021-05-25

Family

ID=35502830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511367A BRPI0511367B8 (pt) 2004-06-11 2005-06-10 uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo

Country Status (16)

Country Link
US (1) US7951777B2 (pt)
EP (1) EP1768689B1 (pt)
JP (1) JP4824682B2 (pt)
KR (2) KR20140057411A (pt)
CN (1) CN1993137B (pt)
AU (1) AU2005251386B8 (pt)
BR (1) BRPI0511367B8 (pt)
CA (1) CA2573439C (pt)
DK (1) DK1768689T3 (pt)
ES (1) ES2523659T3 (pt)
IL (1) IL179931A (pt)
MX (1) MXPA06014462A (pt)
NZ (1) NZ552130A (pt)
RU (1) RU2387454C2 (pt)
WO (1) WO2005120545A1 (pt)
ZA (1) ZA200700070B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1768689T3 (en) * 2004-06-11 2014-12-01 Vectus Biosystems Ltd Compositions and methods for treating cardiovascular disease
CA2574709A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
NZ569401A (en) * 2005-12-09 2012-03-30 Vectus Biosystems Ltd VIP fragments and methods of use
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
WO2009033746A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2738549A1 (en) * 2008-09-25 2010-04-01 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
SG10201501316VA (en) * 2008-10-17 2015-05-28 Vectus Biosystems Pty Ltd Compositions and methods for treatment of kidney disorders
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
NZ595726A (en) * 2009-04-02 2013-06-28 Vectus Biosystems Pty Ltd Compositions and methods for treatment of aortic fibrosis
JP5801807B2 (ja) * 2009-08-14 2015-10-28 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 修飾された血管作動性腸管ペプチド
US8916517B2 (en) 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
SG11201601642WA (en) 2013-09-17 2016-04-28 Vectus Biosystems Ltd Compositions for the treatment of hypertension and/or fibrosis
ES2694375T3 (es) * 2013-09-17 2018-12-20 Vectus Biosystems Limited Composiciones para el tratamiento de la hipertensión y/o de la fibrosis
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
CN110151973A (zh) * 2019-04-25 2019-08-23 上海交通大学医学院附属瑞金医院 一种生物活性多肽pacap的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880826A (en) * 1971-09-17 1975-04-29 Sami I Said Vasoactive intestinal peptide
US3862927A (en) * 1973-02-26 1975-01-28 Sami I Said Process for preparation of vasoactive intestinal peptide
WO1988003928A1 (en) * 1986-11-18 1988-06-02 Senetek Plc Method for inducing vaginal lubrication
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
JPH0840926A (ja) * 1994-08-03 1996-02-13 Yakurigaku Chuo Kenkyusho:Kk 皮膚潰瘍治療薬
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
EP1233811A2 (en) * 1999-11-12 2002-08-28 Leo Rubin Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
AU2002220720B2 (en) 2000-11-28 2006-09-14 Mondobiotech Ag Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US6911430B2 (en) * 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
DK1768689T3 (en) * 2004-06-11 2014-12-01 Vectus Biosystems Ltd Compositions and methods for treating cardiovascular disease
NZ569401A (en) * 2005-12-09 2012-03-30 Vectus Biosystems Ltd VIP fragments and methods of use

Also Published As

Publication number Publication date
HK1102508A1 (en) 2007-11-23
KR101638308B1 (ko) 2016-07-08
NZ552130A (en) 2009-10-30
AU2005251386A1 (en) 2005-12-22
JP2008501723A (ja) 2008-01-24
ES2523659T3 (es) 2014-11-28
US20080108573A1 (en) 2008-05-08
KR20160017121A (ko) 2016-02-15
CN1993137B (zh) 2015-04-22
JP4824682B2 (ja) 2011-11-30
CN1993137A (zh) 2007-07-04
RU2387454C2 (ru) 2010-04-27
AU2005251386B8 (en) 2010-10-14
EP1768689A4 (en) 2009-08-12
EP1768689A1 (en) 2007-04-04
BRPI0511367A (pt) 2007-12-04
BRPI0511367B1 (pt) 2018-05-22
EP1768689B1 (en) 2014-08-20
IL179931A0 (en) 2007-05-15
IL179931A (en) 2013-08-29
CA2573439C (en) 2014-12-09
AU2005251386B2 (en) 2010-05-13
CA2573439A1 (en) 2005-12-22
ZA200700070B (en) 2008-05-28
US7951777B2 (en) 2011-05-31
RU2007101164A (ru) 2008-07-20
WO2005120545A1 (en) 2005-12-22
KR20140057411A (ko) 2014-05-12
MXPA06014462A (es) 2007-05-23
DK1768689T3 (en) 2014-12-01

Similar Documents

Publication Publication Date Title
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
EA200700684A1 (ru) Полиаминные композиции
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BRPI0620566B8 (pt) composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
EA200900662A1 (ru) Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
MY151457A (en) Topical formulation and uses thereof
NO20056252L (no) Terapeutiske og profylaktiske metoder for neuromuskulaere lidelser
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
EA201100072A1 (ru) Новые композиции и способы
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
NZ607892A (en) Tfpi inhibitors and methods of use
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
MX336384B (es) Composiciones que comprenden fragmentos de péptido intestinal vasoactivoa para uso en el tratameinto terapéutico de fibrosis renal.
BRPI0415755A (pt) antagonistas do receptor b1 de bradiquinina
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
EP2510941A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.